Eye Division, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan.
Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan.
Invest Ophthalmol Vis Sci. 2018 Nov 1;59(14):DES116-DES120. doi: 10.1167/iovs.18-24130.
The etiology of dry eye has not been clarified. In the United States, the inflammation theory is supported as the main cause of dry eye, whereas the Asia Dry Eye Society has identified tear instability as the main cause. Based on this tear instability concept, the P2Y2 antagonist Diquas and the mucin secretagogue Mucosta were developed and launched in Japan over the last 5 years, and they have been widely prescribed to patients with dry eye. Moreover, Diquas has also been launched in other Asian countries, such as Korea, Thailand, and Vietnam. This report summarizes the efficacy and characteristics of these two eye drops to improve our understanding of dry eye.
干眼的病因尚未阐明。在美国，炎症理论被认为是干眼的主要病因，而亚洲干眼学会则认为泪液不稳定是主要病因。基于这一泪液不稳定的概念，P2Y2 拮抗剂地夸磷索和粘蛋白促分泌剂环孢素 A 在过去 5 年中在日本被开发和上市，并被广泛用于干眼患者。此外，地夸磷索也在其他亚洲国家（如韩国、泰国和越南）上市。本报告总结了这两种滴眼液的疗效和特点，以加深我们对干眼的认识。
